Efficacy and safety evaluation of Tanreqing Capsules in the treatment of community-acquired pneumonia (phlegm-heat obstructing lung syndrome) in adult: A randomized, double-blind, placebo-controlled, single-c

The First Affiliated Hospital of Guangzhou University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•All the following criteria must be conformed before inclusion:
•?Inpatient aged from 18 to 80;
•?Conforming diagnosis criteria of non-severe CAP;
•?Conforming TCM diagnosis criteria of wind-warmth and lung-heat disease, phlegm-heat obstructing lung syndrome;
•?Patients with clear consciousness, articulateness and adequate understanding of the trail process;
•?Volunteer to participate in clinical trial with favorable compliance and signed informed consent.

•Conforming to any term of the following criteria must be excluded:
•?Patients with severe CAP
•?Women who are pregnant or breastfeeding
•?Patients with TRQC-relative allergic history or ADR history
•?Patients with lung cancer, pulmonary tuberculosis, pulmonary atelectasis or pulmonary edema, etc.;
•?Patients with psychiatric disorder or severe primary diseases of the cardio-cerebrovascular, liver, kidney or hematopoietic system;
•?Patients with chronic alcohol or drug abuse;
•?Patients who are participating in other clinical trials or have participated in other clinical trials within 1 month;
•?Patients with viral, mycoplasma or chlamydia infection suggested by pathogenetic examination.

发起方

The First Affiliated Hospital of Guangzhou University of Chinese Medicine